Cognitive Behavioral Therapy for ARFID
Trial Summary
What is the purpose of this trial?
Randomized controlled trial of an exposure-based behavioral treatment (CBT) in adults with functional dyspepsia who meet criteria for avoidant/restrictive food intake disorder (ARFID) with weight loss.
Do I have to stop taking my current medications for this trial?
The trial does not specify that you must stop taking your current medications, but you need to be on a stable dose for 30 days if you are on any medication.
What data supports the idea that Cognitive Behavioral Therapy for ARFID is an effective treatment?
The available research does not provide specific data on the effectiveness of Cognitive Behavioral Therapy (CBT) for ARFID. Instead, it focuses on the use of CBT and Acceptance and Commitment Therapy (ACT) for depression. These studies suggest that both CBT and ACT are effective for treating depression, with some evidence indicating that CBT might outperform ACT. However, there is no direct evidence in the provided research about CBT's effectiveness for ARFID specifically.12345
What safety data exists for Cognitive Behavioral Therapy and related therapies?
The provided research does not directly address safety data for Cognitive Behavioral Therapy (CBT) or its related therapies like MBCT, DBT, or ACT. However, it does suggest that these therapies are being studied for their feasibility, acceptability, and clinical outcomes in various conditions such as borderline personality disorder, generalized anxiety disorder, and PTSD. This implies that these therapies are generally considered safe enough to be tested in clinical settings, but specific safety data is not detailed in the abstracts provided.678910
Is Cognitive Behavioral Therapy a promising treatment for ARFID?
Yes, Cognitive Behavioral Therapy (CBT) is a promising treatment. It includes approaches like Acceptance and Commitment Therapy (ACT), which has shown effectiveness in improving mental health conditions like anxiety and depression. These therapies help people manage their thoughts and emotions better, leading to improved quality of life.18101112
Research Team
Helen Burton Murray, PhD
Principal Investigator
Massachusetts General Hospital
Eligibility Criteria
This trial is for adults with functional dyspepsia and ARFID, who've lost weight since the onset of FD. They must be stable enough for outpatient care, have not had CBT for FD or ARFID before, can use a computer with webcam, haven't changed medications recently, speak English fluently, and donโt have certain medical conditions like psychosis or recent surgeries.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive cognitive behavioral therapy for functional dyspepsia with avoidant restrictive food intake disorder, consisting of eight 1-hour sessions delivered weekly via a secure video platform
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cognitive Behavioral Therapy
Cognitive Behavioral Therapy is already approved in European Union, United States, Canada for the following indications:
- Anxiety disorders
- Depressive disorders
- Eating disorders
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
- Anxiety disorders
- Depressive disorders
- Eating disorders
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
- Substance use disorders
- Anxiety disorders
- Depressive disorders
- Eating disorders
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator